Winning Stock Forecast: ARRAY Stock Gains 65.65% in 14 Days

(Source: Twitter – @ArrayBioPharma)

Over the period of June 4th to June 18th, Array stock (Array BioPharma Inc., NASDAQ: ARRY) stock price rose by 65.65% following a strong buy rating given by I Know First’s market forecasting algorithm. The Boulder, Colorado-based company primarily focuses their work on discovering, developing, and commercializing small molecule drugs to treat patients with cancer and other diseases. Conducting business in North America, Europe, and the Asia Pacific, the biotechnology firm’s two main drugs, Braftovi and Mektovi, are currently in the market for treating skin-cancer patients who carry certain

Read More

Winning Stock Forecast: Celsion Corp. (NASDAQ: CLSN) Gained Nearly 30% Up Move For Promising Research Pipeline

Winning Stock Forecast

“Celsion continues to make significant progress with our two ongoing clinical development programs for ThermoDox® and GEN-1.  With sound fundamentals and a strong balance sheet, we are well positioned to complete enrollment in our ongoing 550 patient global, pivotal Phase III OPTIMA Study in primary liver cancer and to initiate our 130 patient Phase I/II randomized OVATION II Study in newly diagnosed patients with ovarian cancer in June 2018 and reporting clinical findings from the Phase I cohort of 12 patients of the OVATION II by the end of 2018.” -Michael H. Tardugno, chairman, president and chief executive officer of Celsion


Celsion Corporation (NASDAQ: CLSN), is an oncology drug company focusing on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s portfolio of lead products includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers. The price gained a strong momentum following its release of first quarter 2018 financial results on May 11th. On June 19th, the stock jumped 19.42% and closed the day at $3.32, with markets expecting the research progress it will achieve in the second half of year.

Celsion’s most advanced program is a heat-mediated, tumor-targeting drug delivery technology that employs a novel heat-sensitive liposome engineered to address a range of difficult-to-treat cancers. ThermoDox® is a lyso-thermosensitive liposomal doxorubicin (LTLD), which is applicated to deliver high concentrations of doxorubicin to a target region which is provided with localized heat at 40°C. The LTLD technology leverages mechanisms to allow significant accumulation of liposomes at the tumor site and create openings that release the chemotherapeutic agent directly into the tumor and surrounding vasculature thus supporting drug concentration. When combined with radiofrequency thermal ablation (RFA), the application has the potential to address a range of cancers. A pivotal phase III clinical study of this combination is underway and the enrollment of 550 patients in up to 70 clinical sites is expected to be completed in the third quarter of this year and first interim efficacy analysis are expected to be available in the first half of next year.


For the first quarter ended March 31st, Celsion reported a net loss of $4.5 million, getting better from $5.2 million in the same period of last year. The research and development expenses were $2.7 million, decreased from $3.5 million in the prior year. The less costs are contributed by the company’s tighter clinical development focus on programs like pivotal Phase III OPTIMA Study for the treatment of primary liver cancer and GEN-1 IL-12 immunotherapy for the localized treatment of ovarian cancer. On June 27, the company entered into a $10 million loan agreement with Horizon Technology Finance Corporation, where the funding will be used for working capital and advancement of its product pipelines including ThermoDox® for the treatment of hepatocellular carcinoma, GEN-1 for the treatment of newly diagnosed ovarian cancer and other product pipeline expansion. According to the Q1 report, Celsion’s cash, cash equivalents, short-term investments and interest receivable was $20.8 million, indicating the company’s solvency that short term assets are able to cover long term commitments.

Celsion’s financial health and debt level from 2012 to 2018. Source: Simply Wall Street

On April 17, the I Know First algorithm issued a very bullish forecast on Risk-Conscious Package, where CLSN gained a signal of 30.62 and a predictability of 0.48 over the forecasting period of 3 months.  as part of the fundamental package. Because of the aforementioned factors including market’s confidence on the research process and the growth potential brought by expansions, the stock increased by 32.44% over this period, which was in accordance with our previous forecast.

How to read the I Know First Forecast and Heatmap

Current I Know First subscribers received this bullish CLSN forecast on April 17, 2018.

Subscribe to I Know First’s Daily Market Forecast here.